← Eichor
Study identifier: NCT07519187 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Condition: Relapsed or Refractory Plasma Cell Neoplasms  ·  Sponsor: The General Hospital of Western Theater Command

PhaseEARLY_Phase 1
Planned participants20
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

This description comes directly from the study's public registry record.

Talk to the study team

Hai Yi  ·  13699418229  ·  yihaimail@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

General Hospital of Western Theater Command of PLAChengdu, Chengdu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07519187